CTOs on the Move

Cadent Therapeutics

www.cadenttx.com

 
Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cadenttx.com
  • 60 Hamilton St, Cambridge
    Cambridge, MA USA
  • Phone: 617.949.5229

Executives

Name Title Contact Details

Funding

Cadent Therapeutics raised $40M on 11/15/2018
Cadent Therapeutics raised $15M on 04/29/2020

Similar Companies

Viridian Therapeutics

Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.

Lab Co Inc

Lab Co Inc is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.

Pionyr Immunotherapeutics

Pionyr Immunotherapeutics discovers and develops first-in-class biologic drugs that fine-tune natural immune responses to increase immune defenses for diseases such as cancer, or to dampen immune responses in autoimmune diseases.

CiVi Biopharma

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company`s research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi`s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.